Linker Information
General Information of This Linker
| Linker ID |
LIN0DFWQG
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Alkyl phosphoramide-PEG12-Val-Cit-PAB
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C51H83N6O19P
|
|||||
| Isosmiles |
C#CP(=O)(Nc1ccc(C(=O)NC(C(=O)NC(CCCNC(N)=O)C(=O)Nc2ccc(CO)cc2)C(C)C)cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
|
|||||
| InChI |
InChI=1S/C51H83N6O19P/c1-4-77(64,76-39-38-75-37-36-74-35-34-73-33-32-72-31-30-71-29-28-70-27-26-69-25-24-68-23-22-67-21-20-66-19-18-65-17-16-58)57-45-13-9-43(10-14-45)48(60)56-47(41(2)3)50(62)55-46(6-5-15-53-51(52)63)49(61)54-44-11-7-42(40-59)8-12-44/h1,7-14,41,46-47,58-59H,5-6,15-40H2,2-3H3,(H,54,61)(H,55,62)(H,56,60)(H,57,64)(H3,52,53,63)
|
|||||
| InChIKey |
MQYOGKQEJRQPSY-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1115.222
|
Polar area
|
322.74
|
||
|
Complexity
|
77
|
xlogp Value
|
1.8925
|
|||
|
Heavy Count
|
77
|
Rot Bonds
|
50
|
|||
|
Hbond acc
|
19
|
Hbond Donor
|
8
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Brentuximab-7 [Clinical candidate]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.40 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-7 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
6.40 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-7 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.20 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-7 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.50 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-7 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.